What are the social effects of the new migraine treatment?

26.08.2019 - Health and life science

Migraines affect many people of working age and the social impact beyond the health service is considerable. Migraines involve acute attacks with bursting headaches and the condition has significant effects on patients’ quality of life.

Aimovig is a drug indicated for the prevention of migraine in adults who experience at least four migraine days per month. On behalf of the pharmaceutical company Novartis, Oslo Economics has analyzed the impact on the health service and society as a result of introducing the new drug to the market.

The report can be accessed here (in Norwegian only).

Stroke management in atrial fibrillation patients with rheumatoid arthritis

In collaboration with REMEDY-Centre for Treatment of Rheumatic and Musculoskeletal Diseases at Diakonhjemmet hospital, we have published an article investigating stroke management in atrial fibrillation patients with rheumatoid arthritis. The investigation relies on Norwegian registry data from hospitals and pharmacies.

Evaluation of measures in primary healthcare services

On behalf of the Norwegian Directorate of Health, Oslo Economics and the University of Oslo, in collaboration with several subject matter experts, are conducting a follow-up evaluation of measures in primary healthcare services. This year’s evaluation shows that the situation for general practitioners appears to have improved, while there are still significant challenges related to the population’s access to general medical services.

What are the social effects of the new migraine treatment?

Stroke management in atrial fibrillation patients with rheumatoid arthritis

International experiences with primary health care teams

Evaluation of measures in primary healthcare services

Bergen

Oslo

Berlin